Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Search
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Cooperation with Google Quantum AI
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
Non-small cell lung cancer
Discover more about non-small cell lung cancer, including its symptoms and treatment options.
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Introducing CIAS
Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Digital Transformation Within Our Global IT
Technology is at the heart of our strategy.
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
A tool to aid in the prevention of African swine fever
ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.
Boehringer Ingelheim leader in hatchery vaccination
Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.